Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)
Emma Guttman-Yassky, Alan D. Irvine, Melinda Gooderham, Stephan Weidinger et autres
0 citationsDermatology and Therapy